News

Privo Technologies begins FDA Approved Clinical Trials

BOSTON, Oct. 24, 2018 /PRNewswire/ -- Privo Technologies was granted the green light from the FDA and several hospitals this summer to begin patient recruitment for a prospective clinical trial (NCT03502148) targeting early-stage oral cavity squamous cell carcinoma (OCSCC).  Privo is now...

Contact Us
close slider

Contact Us